[Medical cannabinoids and their indications in chronic pain]

Area of Science:

• Pharmacology
• Neurology
• Pain Management

Background:

• Increasing patient demand for medical cannabinoid prescriptions, particularly for chronic pain management.
• Current medical use of cannabinoids is restricted to specific conditions like multiple sclerosis spasticity and refractory epilepsies.
• Off-label prescriptions require special authorization from the Swiss Federal Office of Public Health (OFSP).

Purpose of the Study:

• To review the current landscape of medical cannabinoid prescriptions.
• To highlight the limited validated indications and the need for special requests for other uses.
• To emphasize the importance of monitoring cannabinoid side effects and the need for further research.

Main Methods:

• Literature review of current medical cannabinoid guidelines and research.
• Analysis of prescription trends and regulatory requirements.
• Discussion of known side effects and areas for future investigation.

Main Results:

• Cannabinoid use is primarily validated for multiple sclerosis spasticity and refractory epilepsies.
• A significant number of prescriptions are for off-label uses, necessitating special authorization.
• Cannabinoid therapy requires careful dose titration and monitoring due to potential dose-dependent side effects.

Conclusions:

• While patient interest in medical cannabinoids is high, particularly for chronic pain, evidence supporting their use is limited.
• Strict monitoring and gradual dosage initiation are crucial to manage potential side effects.
• Further research is imperative to elucidate the mechanisms of action and establish clear indications for broader medical cannabinoid use.